Traditional lab PCR has long been the gold standard in molecular diagnostics — yet its inherent bottlenecks often slow down critical clinical decision-making.
Molecular Point-of-Care Testing (mPOCT) is reshaping infectious disease diagnosis by bringing lab-grade molecular accuracy directly to the patient's side.
Below is a side-by-side comparison across three key dimensions:
🏥 Facility Requirements
Traditional PCR requires a dedicated, zoned molecular laboratory with strict biosafety protocols to prevent amplicon contamination.
Molecular POCT eliminates this barrier entirely. Powered by fully integrated, closed-cartridge systems, testing can be run directly in a regular clinic room, emergency department, or outpatient setting — no specialized lab infrastructure needed.
👩⚕️ Staffing Needs
Conventional PCR workflows rely on trained molecular technologists to manage sample preparation, nucleic acid extraction, amplification setup, and result interpretation.
Molecular POCT is built for non-specialist operators. Nurses and frontline clinical staff can perform tests after brief training, freeing skilled lab teams to focus on higher-complexity work.
⏱️ Turnaround Time
Central lab PCR relies on batch processing, sample transport, and multi-step manual handling — results typically take hours, or even the next day, to return.
Molecular POCT delivers full sample-to-result automation. Load the sample, press start, and receive actionable results within 60 minutes, so clinicians can make treatment decisions during a single patient visit.
🚀 At Chenhui Medical, our two fully automated molecular POCT platforms deliver on all three benefits — and go beyond.
Our Multi-Disc (model:CQ-0404) system delivers high-plex testing (up to 28 targets for each sample) for severe infection diagnosis in hospital inpatient and ICU settings;
Our Flex-Disc (model:CH-0104) system enables rapid, flexible testing for outpatient and primary care.
One sample, one test, clear answers — making targeted, precision therapy possible from the very first consultation. Backed by NMPA and CE-IVD certifications, our technology is ready for global clinical deployment.
Molecular diagnostics does not need to be confined to the central lab. The future is faster, closer to patients, and more accessible than ever.